Repare Therapeutics Stock Last Dividend Paid

RPTX Stock

USD 3.28 0.04 1.20%

Repare Therapeutics fundamentals help investors to digest information that contributes to Repare Therapeutics' financial success or failures. It also enables traders to predict the movement of Repare Stock. The fundamental analysis module provides a way to measure Repare Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Repare Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Repare Therapeutics Company Last Dividend Paid Analysis

Repare Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.

Last Dividend

Last Profit Distribution Amount

Total Shares

More About Last Dividend Paid | All Equity Analysis

Repare Last Dividend Paid Driver Correlations

Understanding the fundamental principles of building solid financial models for Repare Therapeutics is extremely important. It helps to project a fair market value of Repare Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Repare Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Repare Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Repare Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Short Term Investments
Total Assets		0.98	0.95	-0.91	-0.82	0.47	0.61	0.86	0.49	0.98	1.0	0.96	0.99	0.96	0.9	0.65	0.83	0.6
Total Stockholder Equity	0.98		0.98	-0.88	-0.82	0.42	0.61	0.84	0.31	1.0	0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Net Tangible Assets	0.95	0.98		-0.83	-0.86	0.47	0.67	0.87	0.26	0.98	0.95	0.99	0.94	0.99	0.94	0.6	0.89	0.64
Net Debt	-0.91	-0.88	-0.83		0.56	-0.6	-0.37	-0.62	-0.51	-0.88	-0.91	-0.81	-0.94	-0.81	-0.7	-0.34	-0.57	-0.22
Retained Earnings	-0.82	-0.82	-0.86	0.56		-0.45	-0.89	-0.99	-0.27	-0.82	-0.81	-0.9	-0.78	-0.9	-0.87	-0.64	-0.96	-0.77
Accounts Payable	0.47	0.42	0.47	-0.6	-0.45		0.58	0.44	0.39	0.42	0.46	0.44	0.52	0.44	0.44	-0.29	0.31	-0.14
Net Receivables	0.61	0.61	0.67	-0.37	-0.89	0.58		0.82	0.16	0.61	0.61	0.69	0.6	0.69	0.76	0.33	0.75	0.59
Capital Surpluse	0.86	0.84	0.87	-0.62	-0.99	0.44	0.82		0.34	0.84	0.85	0.91	0.82	0.91	0.85	0.68	0.96	0.75
Total Liab	0.49	0.31	0.26	-0.51	-0.27	0.39	0.16	0.34		0.31	0.49	0.31	0.5	0.31	0.36	0.31	0.24	0.2
Net Invested Capital	0.98	1.0	0.98	-0.88	-0.82	0.42	0.61	0.84	0.31		0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Total Current Assets	1.0	0.98	0.95	-0.91	-0.81	0.46	0.61	0.85	0.49	0.98		0.96	0.99	0.96	0.9	0.65	0.83	0.61
Capital Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96		0.94	1.0	0.94	0.66	0.93	0.69
Net Working Capital	0.99	0.97	0.94	-0.94	-0.78	0.52	0.6	0.82	0.5	0.97	0.99	0.94		0.94	0.88	0.57	0.78	0.53
Common Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96	1.0	0.94		0.94	0.66	0.93	0.69
Property Plant Equipment	0.9	0.9	0.94	-0.7	-0.87	0.44	0.76	0.85	0.36	0.9	0.9	0.94	0.88	0.94		0.64	0.89	0.76
Current Deferred Revenue	0.65	0.63	0.6	-0.34	-0.64	-0.29	0.33	0.68	0.31	0.63	0.65	0.66	0.57	0.66	0.64		0.74	0.91
Short Term Debt	0.83	0.84	0.89	-0.57	-0.96	0.31	0.75	0.96	0.24	0.84	0.83	0.93	0.78	0.93	0.89	0.74		0.83
Short Term Investments	0.6	0.61	0.64	-0.22	-0.77	-0.14	0.59	0.75	0.2	0.61	0.61	0.69	0.53	0.69	0.76	0.91	0.83

Click cells to compare fundamentals

Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.

Competition

Predict Repare Therapeutics

Repare Dividend Paid And Capex Coverage Ratio

Dividend Paid And Capex Coverage Ratio

(62.33)

At this time, Repare Therapeutics' Dividend Paid And Capex Coverage Ratio is fairly stable compared to the past year.

Based on the recorded statements, Repare Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Pair Correlation Now

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments

All Next

Launch Module

Repare Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repare Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repare Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Repare Fundamentals

	Return On Equity	-0.41
	Return On Asset	-0.23
	Profit Margin	(1.26) %
	Operating Margin	(1.39) %
	Current Valuation	(37.43 M)
	Shares Outstanding	42.51 M
	Shares Owned By Insiders	0.95 %
	Shares Owned By Institutions	83.62 %
	Number Of Shares Shorted	609.93 K
	Price To Book	0.80 X
	Price To Sales	2.12 X
	Revenue	51.13 M
	Gross Profit	15.11 M
	EBITDA	(114.27 M)
	Net Income	(93.8 M)
	Cash And Equivalents	282.09 M
	Cash Per Share	6.73 X
	Total Debt	3.41 M
	Debt To Equity	0.03 %
	Current Ratio	7.35 X
	Book Value Per Share	4.12 X
	Cash Flow From Operations	(127.16 M)
	Short Ratio	7.12 X
	Earnings Per Share	(1.99) X
	Target Price	12.5
	Number Of Employees	179
	Beta	0.71
	Market Capitalization	141.14 M
	Total Asset	253.9 M
	Retained Earnings	(333.11 M)
	Working Capital	204.61 M
	Net Asset	253.9 M

About Repare Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Repare Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repare Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repare Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC